Agios Pharmaceuticals (AGIO) Tmuɣli n wazal
Agios Pharmaceuticals
Ṛṛbem n lḥedd$32.60Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-0.82%
Asnulfu n AI: AGIO
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Agios Pharmaceuticals, Inc. develops therapeutic agents for the treatment of cancer. The company’s drug development efforts focus on glycolysis, fatty acid metabolism, and autophagy. Agios Pharmaceuticals operates in the United States.
